Investigational Drugs Outside of Clinical Trials: Understanding Expanded Access and Right-to-Try

By WIRB-Copernicus Group
Published: September 2017

Clinical trials can allow access to potentially effective treatment options for patients with a serious disease or condition; however, trials are designed to systematically test investigational therapies. This paper will discuss the complex issues around giving patients access to investigational drugs during the development process.

Please enter in your information below. Fields with an * are required.

Please enter a valid email address to receive an email with a link to download the white paper.   

The WIRB-Copernicus Group® (WCG) is the world’s largest and most trusted provider of regulatory and ethical review services for human research.